A61K 2039/892
Reproductive system [uterus, ovaries, cervix, testes]
Official title: {Reproductive system [uterus, ovaries, cervix, testes]}
A61K2039/892 (Reproductive system [uterus, ovaries, cervix, testes]) appears on 101 US grants and 200 published applications in this corpus.
Search patents in A61K- Granted patents
- 101
- Published applications
- 200
- Assignees
- 103
- Inventors
- 346
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 3 |
| 2003 | 0 | 1 |
| 2004 | 0 | 2 |
| 2005 | 0 | 1 |
| 2006 | 0 | 2 |
| 2007 | 1 | 2 |
| 2008 | 2 | 1 |
| 2009 | 1 | 4 |
| 2010 | 0 | 3 |
| 2011 | 2 | 3 |
| 2012 | 2 | 2 |
| 2013 | 0 | 3 |
| 2014 | 4 | 3 |
| 2015 | 1 | 3 |
| 2016 | 2 | 2 |
| 2017 | 3 | 2 |
| 2018 | 1 | 7 |
| 2019 | 3 | 12 |
| 2020 | 4 | 13 |
| 2021 | 7 | 34 |
| 2022 | 18 | 33 |
| 2023 | 9 | 13 |
| 2024 | 18 | 30 |
| 2025 | 15 | 11 |
| 2026 | 5 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Dendritic cell vaccination sequential to chemotherapy18 Aug 2026US 12,708,644 B2Excoso a.s.
- Tumor antigen peptide26 May 2026US 12,637,500 B2Niigata University
- Humanized antibodies to mucin-16 and methods of use thereof5 May 2026US 12,617,866 B2Eureka Therapeutics, Inc.
- Müllerian inhibiting substance type 2 receptor (MISIIR)-specific CAR T cells for the treatment of ovarian cancer and other gynecologic malignancies24 Feb 2026US 12,559,563 B2The Trustees of the University of Pennsylvania
- Vaccines for treating SARS infections in cancer patients6 Jan 2026US 12,516,296 B2City of Hope
- Combinations of dendritic cell-based vaccines and checkpoint inhibitors13 Aug 2026US 2026/0232776 A1Mayo Foundation for Medical Education and Research
- Dendritic cell-based vaccines and uses thereof30 Jul 2026US 2026/0216306 A1BioVentures, LLC
- Identification of cell surface antigens which induce t-cell responses and their uses2 Jul 2026US 2026/0188423 A1Verdi Solutions GmbH
- Tag72 targeted chimeric antigen receptor modified t cells for treatment of tag72-positive tumors28 May 2026US 2026/0146074 A1City of Hope
- Innate Targeting of Adoptive Cellular Therapies23 Apr 2026US 2026/0108454 A1Qu Biologics Inc.
Most cited
By later US patents
- Induction of cytotoxic T-lymphocyte responses26US 5,695,770 AIDEC Pharmaceuticals Corporation · 1997
- Compositions and methods for treatment of cervical cancer23US 8,114,414 B2The Trustees of the University of Pennsylvania · 2012
- Method of using haptenized ovarian carcinoma tumor cells22US 6,333,028 B1Thomas Jefferson University · 2001
- Induction of cytotoxic T-lymphocyte responses21US 5,709,860 AIDEC Pharmaceuticals Corporation · 1998
- HPV particles and uses thereof11US 9,724,404 B2Aura Biosciences, Inc. · 2017